ReviewEnvironmental health and preventive medicine2011
Promoting effects of nanoparticles/materials on sensitive lung inflammatory diseases.
Review in Environmental health and preventive medicine, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 37 citations in OpenAlex.
- Ultrasound-mediated nanomaterials for the treatment of inflammatory diseases.Ultrasonics sonochemistry · 2025Review
- Current Considerations and Practical Solutions for Overcoming Nanoparticle Interference with LAL Assays and Minimizing Endotoxin Contamination.Methods in molecular biology (Clifton, N.J.) · 2024Article
- Vaping and Lung Inflammation and Injury.Annual review of physiology · 2022Review
- Subchronic and chronic toxicity evaluation of inorganic nanoparticles for delivery applications.Advanced drug delivery reviews · 2019Review
- RNA-DNA fibers and polygons with controlled immunorecognition activate RNAi, FRET and transcriptional regulation of NF-κB in human cells.Nucleic acids research · 2019Article
- Low Dose Carbon Black Nanoparticle Exposure Does Not Aggravate Allergic Airway Inflammation in Mice Irrespective of the Presence of Surface Polycyclic Aromatic Hydrocarbons.Nanomaterials (Basel, Switzerland) · 2018Article
- Ins and Outs in Environmental and Occupational Safety Studies of Asthma and Engineered Nanomaterials.ACS nano · 2017Article
- Current understanding of interactions between nanoparticles and the immune system.Toxicology and applied pharmacology · 2016Review
- Biomarkers of susceptibility: State of the art and implications for occupational exposure to engineered nanomaterials.Toxicology and applied pharmacology · 2016Review
- Pre-clinical immunotoxicity studies of nanotechnology-formulated drugs: Challenges, considerations and strategy.Journal of controlled release : official journal of the Controlled Release Society · 2015Review
- Dose ranging, expanded acute toxicity and safety pharmacology studies for intravenously administered functionalized graphene nanoparticle formulations.Biomaterials · 2014Article
- Inhibition of phosphoinositol 3 kinase contributes to nanoparticle-mediated exaggeration of endotoxin-induced leukocyte procoagulant activity.Nanomedicine (London, England) · 2014Article
- Identification and avoidance of potential artifacts and misinterpretations in nanomaterial ecotoxicity measurements.Environmental science & technology · 2014Article
- Sneezing and allergic dermatitis were increased in engineered nanomaterial handling workers.Industrial health · 2014Article
- Nanoparticles and the blood coagulation system. Part II: safety concerns.Nanomedicine (London, England) · 2013Review
- Direct effects of carbon nanotubes on dendritic cells induce immune suppression upon pulmonary exposure.ACS nano · 2011Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Although the adverse health effects of nanoparticles/materials have been proposed and are being clarified, their facilitating effects on preexisting pathological conditions have not been fully established. We provide insights into the environmental immunotoxicity of nanoparticles as an aggravating factor in hypersusceptible subjects, especially those with respiratory disorders, using our in vivo models. We first examined the effects of nanoparticles/materials on lung inflammation induced by bacterial endotoxin (lipopolysaccharide) as a test model against innate immunity, and demonstrated that nanoparticles instilled through both an intratracheal tube and an inhalation system can exacerbate lung inflammation. Secondly, we examined the effects of nanoparticles/materials on allergic pathophysiology, and showed that repetitive pulmonary exposure to nanoparticles has aggravating effects on allergic airway inflammation, including adjuvant effects on Th2-milieu. Taken together, nanoparticle exposure may synergistically facilitate pathological inflammatory conditions in the lung via both innate and adaptive immunological abnormalities.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.